Phase II pink eye drug to be exclusive with manufacturer

Opko has obtained exclusive rights to a molecular agent (Doxovir, Redox Pharmaceutical Corp.), which is in phase II clinical development for the treatment of viral conjunctivitis and other viral infections.

Miami-Opko has obtained exclusive rights to a molecular agent (Doxovir, Redox Pharmaceutical Corp.), which is in phase II clinical development for the treatment of viral conjunctivitis and other viral infections.

This drug is in a class that demonstrates potent anti-viral activity and non-steroidal anti-inflammatory properties with good safety in preclinical and human clinical testing.

"Viral conjunctivitis, popularly known as 'pink eye,' is among the most common eye disorders, yet patients have no real treatment options for this unsightly, uncomfortable, and debilitating condition," said Naveed Shams, MD, PhD, chief medical officer and senior vice president of research and development of Opko. "The potent anti-viral activity of CTC-96, its anti-inflammatory properties and its good safety profile make it a potentially ideal candidate for the treatment of viral conjunctivitis."

The anti-viral mechanism demonstrated efficiency against multiple viral infections in preclinical studies, disrupting viral lifecycle by interfering with viral assembly. The drug has successfully completed randomized double-blinded phase I trials for the treatment of adenovirus keratoconjunctivitis and for the treatment of ocular herpes infection.